Covista (CVSA) has been in focus after delivering better than expected revenue and profit, reaffirming its fiscal 2026 guidance, and combining that with an accelerated share repurchase and new buyback authorization.

Covista’s recent earnings beat, guidance reaffirmation, and debt refinancing arrive after a period of mixed sentiment, with profit taking earlier in the year but a 10.04% 1 month share price return and a very large 3 year total shareholder return that together suggest underlying momentum is still intact despite shorter term caution.

If this update has you thinking about where else strong execution and resilient demand might be showing up, take a look at our screener of 33 healthcare AI stocks as potential next ideas to research.

With the stock up 10.04% over the past month and trading at roughly a 50% discount to the US$161 analyst price target and intrinsic estimate, you have to ask: is there still a genuine opportunity here, or is the market already baking in future growth?

Preferred P/E of 14.3x: Is it justified?

On a simple earnings yardstick, Covista trades on a P/E of 14.3x, which screens as inexpensive compared with both its own sector and closer peers.

P/E compares the share price to earnings per share, so a lower P/E can suggest investors are not paying as much for each dollar of current earnings. For a profitable education provider with positive net income of $253.98m and high quality earnings, that matters because the business model already converts revenue into profit rather than asking investors to wait for distant upside.

Here, the P/E of 14.3x sits below the US Consumer Services industry average of 17.7x and also below the 17.3x average for its peer group. This gap implies the market is pricing Covista more conservatively than comparable companies. Against an estimated fair P/E of 21.6x from the SWS fair ratio model, the current multiple also sits well under a level the market could theoretically move towards if sentiment and expectations aligned with that fair ratio assessment.

Result: Price-to-Earnings of 14.3x (UNDERVALUED)

However, you still have to watch for regulatory changes in higher education, as well as any slowdown in enrollment demand across Covista’s nursing and medical programs.

Another View: What Does The DCF Say?

While a 14.3x P/E hints at a modest price for Covista, our DCF model presents an estimated future cash flow value of $212.17 per share compared with a current price of $105.11. That difference suggests potential upside, but how comfortable are you with the assumptions behind it?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Covista for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this all sounds optimistic and you want to stress test it yourself, move quickly, review the full picture, and weigh up the 5 key rewards before deciding what it means for you.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, now is the moment to widen your search and see what other opportunities the Simply Wall St screener surfaces.

• Spot potential value plays early by scanning our list of 48 high quality undervalued stocks that currently appear attractively priced based on their fundamentals.
• Prioritise peace of mind and review 68 resilient stocks with low risk scores that the model scores with lower overall risk profiles.
• Hunt for lesser known opportunities by checking the screener containing 26 high quality undiscovered gems that have solid underlying metrics but are not widely followed yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.